FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.941,09 -1.262,74 (-2,10%)
Atai Life Sciences N.V. (ATAI)
Dopo ore:
| Chiusura precedente | 1,8400 |
| Aperto | 1,8500 |
| Denaro | 1,9100 x 800 |
| Lettera | 1,9400 x 600 |
| Min-Max giorno | 1,8250 - 1,9425 |
| Intervallo di 52 settimane | 1,0250 - 2,8500 |
| Volume | |
| Media Volume | 1.616.222 |
| Capitalizzazione | 323,107M |
| Beta (5 anni mensile) | 0,98 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2500 |
| Prossima data utili | 07 mag 2024 - 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,68 |
GlobeNewswireatai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at 8:30 A.M. ET Location: New
- GlobeNewswire
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comparable to those achieved with IV administrationCompany plans to further optimize VLS-01 in preparation for a Phase 2 study in treatment-resistant depression (TRD) NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“at
- GlobeNewswire
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company’s participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET Location: New York, NY A webcast o
